SYNTARA LIMITED - Announcements

Market Cap $27.46M Add to my watchlist

Healthcare

Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug... Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

SNT	Pharmaxis Quarterly Investor Conference Call		17/02/14	22.73KB	Share
SNT	Appendix 3B - Exercise of employee options		14/02/14	87.54KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/14	136.29KB	Share
SNT	Appendix 3B - Exercise of employee options		12/12/13	87.65KB	Share
SNT	Scottish Medicines Consortium Accepts Bronchitol for CF Use	PRICE SENSITIVE	10/12/13	111.59KB	Share
SNT	Change of Director's Interest Notice		02/12/13	70.41KB	Share
SNT	Appendix 3B		28/11/13	94.13KB	Share
SNT	Results of Meeting		28/11/13	90.84KB	Share
SNT	CEO Presentation to AGM		27/11/13	728.85KB	Share
SNT	Chairman's Address to Shareholders		27/11/13	114.3KB	Share
SNT	Change of Director's Interest Notice		04/11/13	70.1KB	Share
SNT	Appendix 3B - option exercise		04/11/13	87.65KB	Share
SNT	Appendix 3B - Employee restricted shares and options		04/11/13	92.43KB	Share
SNT	Pharmaxis Elects to Receive Full NovaQuest Investment	PRICE SENSITIVE	30/10/13	109.35KB	Share
SNT	Change in substantial holding		23/10/13	69.64KB	Share
SNT	Change in substantial holding		22/10/13	63.52KB	Share
SNT	Notice of Annual General Meeting/Proxy Form		21/10/13	528.4KB	Share
SNT	Pharmaxis Quarterly Investor Briefing		16/10/13	332.34KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	16/10/13	101.93KB	Share
SNT	PHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL		15/10/13	22.73KB	Share
SNT	2013 Annual Report to Shareholders		25/09/13	543.69KB	Share
SNT	Final Director's Interest Notice - R van den Broek		19/09/13	9.84KB	Share
SNT	Final Director's Interest Notice - J Villiger		19/09/13	9.91KB	Share
SNT	Pharmaxis Announces Two Board Retirements		19/09/13	102.64KB	Share
PRX +AGI AGO AIA AMX API ARF BBG BND BSE BTR CCP CLE CLH CMW COK CPL CRH CTD CWP DML DTE EHL FGE FKP FML RHK FSF GRR GRY GXL GXY HGO INA ISU IVA LYC MAH MBN MCE MDL MIO LCL MOC MPO MXI MCY MYX DTZ NVT NWS NWT PEM PPT SNT RED RMS RXM SGH SGN SHV SIV SKC SKT TGR TIX PAC VRL VRT ZSP	S&P DJ Indices Announces September Quarterly Rebalance		06/09/13	57.27KB	Share
SNT	Pharmaxis Announces Delay to French Pricing for Bronchitol	PRICE SENSITIVE	29/08/13	117.25KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	15/08/13	417.76KB	Share
SNT	Change in substantial holding		01/08/13	62.01KB	Share
SNT	Appendix 3B - Exercise of employee options		29/07/13	87.78KB	Share
SNT	PHARMAXIS ANNOUNCES IMPROVED PBS LISTING OF BRONCHITOL	PRICE SENSITIVE	18/07/13	109.09KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	17/07/13	102.19KB	Share
SNT	Investor Presentation - Quarterly Briefing June 2013		17/07/13	406.9KB	Share
SNT	PHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL		16/07/13	22.74KB	Share
SNT	Pharmaxis Awarded Two ARC Linkage Grants	PRICE SENSITIVE	05/07/13	125.75KB	Share
SNT	European CF Clinical Trial in Paediatric Patients Begins	PRICE SENSITIVE	20/06/13	126.62KB	Share
SNT	Pharmaxis Presents New Analyses of Pooled CF Data at EU Meet	PRICE SENSITIVE	18/06/13	124.41KB	Share
SNT	App 3B - Grant of employee Options		07/06/13	93.35KB	Share
SNT	CEO Remuneration and Employee Performance Rights		07/06/13	126.18KB	Share
SNT	Aridol FDA Import Restrictions	PRICE SENSITIVE	03/06/13	115.63KB	Share
SNT	Investor Presentation - Business Plan		28/05/13	821.54KB	Share
SNT	Outcome of Business Review	PRICE SENSITIVE	28/05/13	137.37KB	Share
SNT	Investor Conference Call - Results of Business Plan		23/05/13	22.86KB	Share
SNT	Pharmaxis Appoints Bronchitol Distributor for Poland	PRICE SENSITIVE	22/05/13	109.57KB	Share
SNT	Pharmaxis Agrees Key Cystic Fibrosis Trial Paramaters with F		21/05/13	159.3KB	Share
SNT	Ceasing to be a substantial holder		20/05/13	51.49KB	Share
SNT	Ceasing to be a substantial holder		17/05/13	51.4KB	Share
SNT	FDA Meeting, Business Review Announcement End of May	PRICE SENSITIVE	14/05/13	121.28KB	Share
SNT	Becoming a substantial holder		06/05/13	58.57KB	Share
SNT	Change of Director's Interest Notice		03/05/13	70.99KB	Share
SNT	Ceasing to be a substantial holder		29/04/13	19.89KB	Share
SNT	Investor presentation - B305		24/04/13	226.2KB	Share
SNT	PHASE 3 CLINICAL TRIAL IN BRONCHIECTASIS (B305)	PRICE SENSITIVE	24/04/13	110.13KB	Share
SNT	Pharmaxis Conference Call		23/04/13	21.59KB	Share
SNT	Trading Halt	PRICE SENSITIVE	22/04/13	53.59KB	Share
SNT	Change in substantial holding		15/04/13	14.45KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	10/04/13	109.59KB	Share
SNT	Investor Presentation - April 2013		10/04/13	1MB	Share
SNT	Pharmaxis Announces Bronchitol Distributor for Brazil		10/04/13	83.42KB	Share
SNT	Quarterly Investor Conference Call		10/04/13	21.5KB	Share
SNT	PHARMAXIS RECEIVES COMPLETE RESPONSE LETTER FROM FDA	PRICE SENSITIVE	19/03/13	103.65KB	Share
SNT	Trading Halt	PRICE SENSITIVE	19/03/13	53.73KB	Share
SNT	Initial Director's Interest Notice		12/03/13	65.82KB	Share
SNT	Final Director's Interest Notice		12/03/13	11KB	Share
SNT	Pharmaxis Appoints Gary Phillips New Chief Executive Officer	PRICE SENSITIVE	12/03/13	114.99KB	Share
SNT	Bronchiectasis Phase 3 Trial Milestone	PRICE SENSITIVE	08/03/13	93.9KB	Share
SNT	Half Year Report and Accounts	PRICE SENSITIVE	15/02/13	217.67KB	Share
SNT	Becoming a substantial holder		04/02/13	568.76KB	Share
SNT	Pharmaxis Announces US$40 million Financing Areement	PRICE SENSITIVE	31/01/13	85.06KB	Share
SNT	Pharmaxis Receives Negative Recommendation from PADAC	PRICE SENSITIVE	31/01/13	114.67KB	Share
SNT	Trading Halt	PRICE SENSITIVE	29/01/13	55.06KB	Share
SNT	December 2012 Quarterly Report to Shareholders		23/01/13	258.5KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	23/01/13	109.27KB	Share
SNT	Investor Conference Call and Quarterly Report		22/01/13	21.6KB	Share
SNT	Appendix 3B - Exercise of Employee Options		13/11/12	92.23KB	Share
SNT	Appendix 3B - Exercise of Employee Options		08/11/12	92.28KB	Share
SNT	Appendix 3B - Option Exercise		30/10/12	92.27KB	Share
SNT	IMPORTANT MILESTONE BRONCHITOL APPROVED BY NICE IN UK	PRICE SENSITIVE	26/10/12	85.26KB	Share
SNT	Trading Halt	PRICE SENSITIVE	26/10/12	41.95KB	Share
SNT	Change of Director's Interest Notice		18/10/12	71.39KB	Share
SNT	Change of Director's Interest Notice		18/10/12	70.88KB	Share
SNT	Appendix 3B - Option Issue		18/10/12	100.22KB	Share
SNT	Results of Meeting		18/10/12	79.16KB	Share
SNT	CEO Presentation to AGM		17/10/12	4.33MB	Share
SNT	Chairman's Address to Shareholders		17/10/12	86.09KB	Share
SNT	September 2012 Quarterly Report to Sharehholders		10/10/12	1.86MB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	10/10/12	109.01KB	Share
SNT	Presentation at North American Cystic Fibrosis Conference		10/10/12	106.4KB	Share
SNT	Quarterly Report and Investor Conference Call		08/10/12	21.58KB	Share
SNT	Response to ASX Price Query	PRICE SENSITIVE	08/10/12	161.43KB	Share
SNT	Pharmaxis Receives Maximum Extension to German Patent	PRICE SENSITIVE	27/09/12	80.57KB	Share
SNT	Investor Presentation		13/09/12	4.73MB	Share
SNT	Annual Report to shareholders 2012		11/09/12	1.12MB	Share
SNT	Notice of Annual General Meeting/Proxy Form 2012		11/09/12	639.95KB	Share
SNT	Investor Presentation		16/08/12	4.5MB	Share
SNT	Independent Audit Report - 30 June 2012		10/08/12	141.56KB	Share
SNT	Proposed Grant of Options to New Director		10/08/12	77KB	Share
SNT	Appendix 3B - Employee Shares		10/08/12	99.3KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	10/08/12	265.62KB	Share
SNT	US FDA Accepts Bronchitol New Drug Application for Review	PRICE SENSITIVE	02/08/12	80.48KB	Share
SNT	Initial Director's Interest Notice		25/07/12	66.5KB	Share

SNTPharmaxis Quarterly Investor Conference Call
17/02/14		22.73KB	Share
SNTAppendix 3B - Exercise of employee options
14/02/14		87.54KB	Share
SNTAppendix 4C - quarterly
30/01/14	PRICE SENSITIVE	136.29KB	Share
SNTAppendix 3B - Exercise of employee options
12/12/13		87.65KB	Share
SNTScottish Medicines Consortium Accepts Bronchitol for CF Use
10/12/13	PRICE SENSITIVE	111.59KB	Share
SNTChange of Director's Interest Notice
02/12/13		70.41KB	Share
SNTAppendix 3B
28/11/13		94.13KB	Share
SNTResults of Meeting
28/11/13		90.84KB	Share
SNTCEO Presentation to AGM
27/11/13		728.85KB	Share
SNTChairman's Address to Shareholders
27/11/13		114.3KB	Share
SNTChange of Director's Interest Notice
04/11/13		70.1KB	Share
SNTAppendix 3B - option exercise
04/11/13		87.65KB	Share
SNTAppendix 3B - Employee restricted shares and options
04/11/13		92.43KB	Share
SNTPharmaxis Elects to Receive Full NovaQuest Investment
30/10/13	PRICE SENSITIVE	109.35KB	Share
SNTChange in substantial holding
23/10/13		69.64KB	Share
SNTChange in substantial holding
22/10/13		63.52KB	Share
SNTNotice of Annual General Meeting/Proxy Form
21/10/13		528.4KB	Share
SNTPharmaxis Quarterly Investor Briefing
16/10/13		332.34KB	Share
SNTAppendix 4C - quarterly
16/10/13	PRICE SENSITIVE	101.93KB	Share
SNTPHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL
15/10/13		22.73KB	Share
SNT2013 Annual Report to Shareholders
25/09/13		543.69KB	Share
SNTFinal Director's Interest Notice - R van den Broek
19/09/13		9.84KB	Share
SNTFinal Director's Interest Notice - J Villiger
19/09/13		9.91KB	Share
SNTPharmaxis Announces Two Board Retirements
19/09/13		102.64KB	Share
PRX +AGI AGO AIA AMX API ARF BBG BND BSE BTR CCP CLE CLH CMW COK CPL CRH CTD CWP DML DTE EHL FGE FKP FML RHK FSF GRR GRY GXL GXY HGO INA ISU IVA LYC MAH MBN MCE MDL MIO LCL MOC MPO MXI MCY MYX DTZ NVT NWS NWT PEM PPT SNT RED RMS RXM SGH SGN SHV SIV SKC SKT TGR TIX PAC VRL VRT ZSPS&P DJ Indices Announces September Quarterly Rebalance
06/09/13		57.27KB	Share
SNTPharmaxis Announces Delay to French Pricing for Bronchitol
29/08/13	PRICE SENSITIVE	117.25KB	Share
SNTPreliminary Final Report
15/08/13	PRICE SENSITIVE	417.76KB	Share
SNTChange in substantial holding
01/08/13		62.01KB	Share
SNTAppendix 3B - Exercise of employee options
29/07/13		87.78KB	Share
SNTPHARMAXIS ANNOUNCES IMPROVED PBS LISTING OF BRONCHITOL
18/07/13	PRICE SENSITIVE	109.09KB	Share
SNTAppendix 4C - quarterly
17/07/13	PRICE SENSITIVE	102.19KB	Share
SNTInvestor Presentation - Quarterly Briefing June 2013
17/07/13		406.9KB	Share
SNTPHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL
16/07/13		22.74KB	Share
SNTPharmaxis Awarded Two ARC Linkage Grants
05/07/13	PRICE SENSITIVE	125.75KB	Share
SNTEuropean CF Clinical Trial in Paediatric Patients Begins
20/06/13	PRICE SENSITIVE	126.62KB	Share
SNTPharmaxis Presents New Analyses of Pooled CF Data at EU Meet
18/06/13	PRICE SENSITIVE	124.41KB	Share
SNTApp 3B - Grant of employee Options
07/06/13		93.35KB	Share
SNTCEO Remuneration and Employee Performance Rights
07/06/13		126.18KB	Share
SNTAridol FDA Import Restrictions
03/06/13	PRICE SENSITIVE	115.63KB	Share
SNTInvestor Presentation - Business Plan
28/05/13		821.54KB	Share
SNTOutcome of Business Review
28/05/13	PRICE SENSITIVE	137.37KB	Share
SNTInvestor Conference Call - Results of Business Plan
23/05/13		22.86KB	Share
SNTPharmaxis Appoints Bronchitol Distributor for Poland
22/05/13	PRICE SENSITIVE	109.57KB	Share
SNTPharmaxis Agrees Key Cystic Fibrosis Trial Paramaters with F
21/05/13		159.3KB	Share
SNTCeasing to be a substantial holder
20/05/13		51.49KB	Share
SNTCeasing to be a substantial holder
17/05/13		51.4KB	Share
SNTFDA Meeting, Business Review Announcement End of May
14/05/13	PRICE SENSITIVE	121.28KB	Share
SNTBecoming a substantial holder
06/05/13		58.57KB	Share
SNTChange of Director's Interest Notice
03/05/13		70.99KB	Share
SNTCeasing to be a substantial holder
29/04/13		19.89KB	Share
SNTInvestor presentation - B305
24/04/13		226.2KB	Share
SNTPHASE 3 CLINICAL TRIAL IN BRONCHIECTASIS (B305)
24/04/13	PRICE SENSITIVE	110.13KB	Share
SNTPharmaxis Conference Call
23/04/13		21.59KB	Share
SNTTrading Halt
22/04/13	PRICE SENSITIVE	53.59KB	Share
SNTChange in substantial holding
15/04/13		14.45KB	Share
SNTAppendix 4C - quarterly
10/04/13	PRICE SENSITIVE	109.59KB	Share
SNTInvestor Presentation - April 2013
10/04/13		1MB	Share
SNTPharmaxis Announces Bronchitol Distributor for Brazil
10/04/13		83.42KB	Share
SNTQuarterly Investor Conference Call
10/04/13		21.5KB	Share
SNTPHARMAXIS RECEIVES COMPLETE RESPONSE LETTER FROM FDA
19/03/13	PRICE SENSITIVE	103.65KB	Share
SNTTrading Halt
19/03/13	PRICE SENSITIVE	53.73KB	Share
SNTInitial Director's Interest Notice
12/03/13		65.82KB	Share
SNTFinal Director's Interest Notice
12/03/13		11KB	Share
SNTPharmaxis Appoints Gary Phillips New Chief Executive Officer
12/03/13	PRICE SENSITIVE	114.99KB	Share
SNTBronchiectasis Phase 3 Trial Milestone
08/03/13	PRICE SENSITIVE	93.9KB	Share
SNTHalf Year Report and Accounts
15/02/13	PRICE SENSITIVE	217.67KB	Share
SNTBecoming a substantial holder
04/02/13		568.76KB	Share
SNTPharmaxis Announces US$40 million Financing Areement
31/01/13	PRICE SENSITIVE	85.06KB	Share
SNTPharmaxis Receives Negative Recommendation from PADAC
31/01/13	PRICE SENSITIVE	114.67KB	Share
SNTTrading Halt
29/01/13	PRICE SENSITIVE	55.06KB	Share
SNTDecember 2012 Quarterly Report to Shareholders
23/01/13		258.5KB	Share
SNTAppendix 4C - quarterly
23/01/13	PRICE SENSITIVE	109.27KB	Share
SNTInvestor Conference Call and Quarterly Report
22/01/13		21.6KB	Share
SNTAppendix 3B - Exercise of Employee Options
13/11/12		92.23KB	Share
SNTAppendix 3B - Exercise of Employee Options
08/11/12		92.28KB	Share
SNTAppendix 3B - Option Exercise
30/10/12		92.27KB	Share
SNTIMPORTANT MILESTONE BRONCHITOL APPROVED BY NICE IN UK
26/10/12	PRICE SENSITIVE	85.26KB	Share
SNTTrading Halt
26/10/12	PRICE SENSITIVE	41.95KB	Share
SNTChange of Director's Interest Notice
18/10/12		71.39KB	Share
SNTChange of Director's Interest Notice
18/10/12		70.88KB	Share
SNTAppendix 3B - Option Issue
18/10/12		100.22KB	Share
SNTResults of Meeting
18/10/12		79.16KB	Share
SNTCEO Presentation to AGM
17/10/12		4.33MB	Share
SNTChairman's Address to Shareholders
17/10/12		86.09KB	Share
SNTSeptember 2012 Quarterly Report to Sharehholders
10/10/12		1.86MB	Share
SNTAppendix 4C - quarterly
10/10/12	PRICE SENSITIVE	109.01KB	Share
SNTPresentation at North American Cystic Fibrosis Conference
10/10/12		106.4KB	Share
SNTQuarterly Report and Investor Conference Call
08/10/12		21.58KB	Share
SNTResponse to ASX Price Query
08/10/12	PRICE SENSITIVE	161.43KB	Share
SNTPharmaxis Receives Maximum Extension to German Patent
27/09/12	PRICE SENSITIVE	80.57KB	Share
SNTInvestor Presentation
13/09/12		4.73MB	Share
SNTAnnual Report to shareholders 2012
11/09/12		1.12MB	Share
SNTNotice of Annual General Meeting/Proxy Form 2012
11/09/12		639.95KB	Share
SNTInvestor Presentation
16/08/12		4.5MB	Share
SNTIndependent Audit Report - 30 June 2012
10/08/12		141.56KB	Share
SNTProposed Grant of Options to New Director
10/08/12		77KB	Share
SNTAppendix 3B - Employee Shares
10/08/12		99.3KB	Share
SNTPreliminary Final Report
10/08/12	PRICE SENSITIVE	265.62KB	Share
SNTUS FDA Accepts Bronchitol New Drug Application for Review
02/08/12	PRICE SENSITIVE	80.48KB	Share
SNTInitial Director's Interest Notice
25/07/12		66.5KB	Share

REFRESH

First 6 7 8 9 10

(20min delay)
Last 2.3¢		Change -0.001(4.17%)		Mkt cap ! $27.46M

Open	High	Low	Value	Volume
2.4¢	2.4¢	2.2¢	$36.31K	1.599M

Buyers (Bids)

No.	Vol.	Price($)
5	793867	2.1¢

Sellers (Offers)

Price($)	Vol.	No.
2.4¢	242619	3

View Market Depth

No.	Vol.	Price($)
5	793867	0.021
14	3542674	0.020
4	1315798	0.019
3	1002999	0.018
6	578189	0.017

Price($)	Vol.	No.
0.024	242619	3
0.025	103870	3
0.026	50000	1
0.027	200000	1
0.028	500000	1

Last trade - 15.46pm 25/06/2024 (20 minute delay)


Last 2.2¢		Change -0.001 ( 8.33 %)
Open	High	Low	Volume
2.2¢	2.3¢	2.2¢	209216
Last updated 15.34pm 25/06/2024 ?

SNT (ASX) Chart

SYNTARA LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available